Clinical profile and demographic distribution of Fuchs’ endothelial dystrophy: An electronic medical record–driven big data analytics from an eye care network in India

Anthony Vipin Das1,2, Sunita Chaurasia3

Purpose: To describe the demographics and clinical profile of Fuchs’ endothelial corneal dystrophy (FECD) in patients presenting to a multi-tiered ophthalmology hospital network in India. Methods: This cross-sectional hospital-based study included 3,082,727 new patients presenting between August 2010 and December 2021. Patients with a clinical diagnosis of FECD in at least one eye were included as cases. The data were collected using an electronic medical record system. Results: Overall, 2570 (0.08%) patients were diagnosed with FECD. The majority of the patients were female (65.53%) and were predominantly adults (99.92%). The most common age group at presentation was during the seventh decade of life with 867 patients (33.74%). The overall prevalence was higher in patients from a higher socioeconomic status (0.1%) presenting from the urban geography (0.09%) and in retired individuals (0.4%). About half of the 5,140 eyes had mild or no visual impairment (<20/70) in 2643 eyes (51.42%) followed by moderate visual impairment (>20/70 to 20/200) in 708 eyes (13.77%). The average logMAR was 0.61 ± 0.81 at presentation. The most documented corneal signs were guttae (76.63%), corneal scar (23%) and stromal edema (21.73%). The most associated ocular comorbidity was cataract (47.32%) followed by glaucoma (5.39%). More than a tenth of the affected eyes required a surgical intervention of endothelial keratoplasty (15.58%). Conclusion: FECD more commonly affects females presenting during the seventh decade of life. Majority of the eyes had mild or no visual impairment and endothelial keratoplasty is warranted in a tenth of the affected eyes.

Key words: Big data, cornea, electronic medical records, Fuchs’ endothelial dystrophy, India

Fuchs’ corneal endothelial dystrophy (FECD) is characterized by the development of guttae in the Descemet membrane, resulting in endothelial dysfunction.[10] The morphological and functional abnormalities in the corneal endothelium results in corneal edema leading to vision impairment and pain due to the epithelial bullae in advanced cases. FECD was first described by Professor Ernest Fuchs in 1910 as “dystrophia epithelialis” where a slowly progressive corneal clouding more in the inferior cornea was associated with diurnal variation of symptoms in elderly patients.[3] While the late-onset form predominantly affects patients in the elderly age group above 40 years of age, the early-onset form can also affect younger populations.[3,4] The prevalence of FECD has been reported in varying degrees in the population ranging from 3.7%–11%. In United States, it is reported between 3.9%–6.62% of the population aged above 40 years.[1,4] in Iceland, it is reported to be 9.2% of the population above the age of 50 years[3,4] and Japan reported a lower prevalence rate of 3.3%.[5] A greater prevalence of FECD has been reported in females than males in the literature.[1,3,5,7] A genetic inheritance of autosomal dominant (AD) pattern has been described in the early-onset disease of two mutations in the Col8A2 gene located on chromosome 1p34.3-p32 that encodes for the α2 polypeptide of collagen type VIII.[8] Acquired corneal endotheliopathies accounted for 8.3% of severe visual impairment and blindness in eyes affected with corneal diseases.[9] Studies from India have shown that FECD accounted for 41.89% of the overall corneal dystrophies[9] and accounted for 20.4% of the endothelial keratoplasty that were performed.[11]

The purpose of the current study was to present the clinical and demographic profile of Fuchs’ endothelial dystrophy at a large multi-tiered ophthalmology network in India using electronic medical record–driven analytics.

Methods

Study Design, Period, Location and Approval: This cross-sectional, observational, hospital-based study included all patients presenting between August 2010 and December 2021 in patients presenting to a multi-tiered ophthalmology hospital network in India. Patients with a clinical diagnosis of FECD in at least one eye were included as cases. The data were collected using an electronic medical record system.

Results: Overall, 2570 (0.08%) patients were diagnosed with FECD. The majority of the patients were female (65.53%) and were predominantly adults (99.92%). The most common age group at presentation was during the seventh decade of life with 867 patients (33.74%). The overall prevalence was higher in patients from a higher socioeconomic status (0.1%) presenting from the urban geography (0.09%) and in retired individuals (0.4%). About half of the 5,140 eyes had mild or no visual impairment (<20/70) in 2643 eyes (51.42%) followed by moderate visual impairment (>20/70 to 20/200) in 708 eyes (13.77%). The average logMAR was 0.61 ± 0.81 at presentation. The most documented corneal signs were guttae (76.63%), corneal scar (23%) and stromal edema (21.73%). The most associated ocular comorbidity was cataract (47.32%) followed by glaucoma (5.39%). More than a tenth of the affected eyes required a surgical intervention of endothelial keratoplasty (15.58%).

Conclusion: FECD more commonly affects females presenting during the seventh decade of life. Majority of the eyes had mild or no visual impairment and endothelial keratoplasty is warranted in a tenth of the affected eyes.

Key words: Big data, cornea, electronic medical records, Fuchs’ endothelial dystrophy, India
to a multi-tiered ophthalmology network located in India.[12] The patient or the parents or guardians of the patient filled out a standard consent form for electronic data privacy at the time of registration. None of the identifiable parameters of the patient were used for analysis of the data. The clinical data of each patient who underwent a comprehensive ophthalmic examination was entered into a browser-based electronic medical records system (eyeSmart EMR) by uniformly trained ophthalmic personnel and supervised by an ophthalmologist using a standardized template.[13] The study adhered to the Declaration of Helsinki and was approved by the Institutional Ethics Committee (LEC 04-19-027).

**Cases:** A total of 3,082,727 new patients presented to the tertiary and secondary centers of the multi-tiered ophthalmology network during the study period. The eyeSmart EMR was screened for patients with a documented ocular diagnosis of Fuchs’ endothelial dystrophy in one or both eyes. The diagnosis of FECD was made based on typical clinical features such as guttae in the central cornea, thickening of the Descemet membrane, pigments on the endothelial surface, with or without subepithelial changes, along with specular microscopy wherever applicable. Histology of the Descemet membrane showing excrescences or guttae was corroborative with the clinical diagnosis in those eyes that underwent keratoplasty. Figs. 1(a–d) and 2(a–f) show the representative photographs of some patients diagnosed with FECD. A total of 2570 patient records were identified using this search strategy and were labelled as cases. A total of 5140 eyes diagnosed with Fuchs’ endothelial dystrophy in the above patients were further analyzed for clinical information.

**Data Retrieval and Processing:** The data of 2570 patients included in this study were retrieved from the electronic medical record database and segregated into a Microsoft Excel sheet. The columns included the data on patient demographics, clinical presentation, ocular diagnosis and treatment information and were exported for analysis. The Excel sheet with the required data was then used for analysis using the appropriate statistical software. Standardized definitions were used for occupation and socioeconomic status.[13] The visual acuity was classified according to the World Health Organization (WHO) guidelines.[14]

**Statistical Analysis:** Descriptive statistics using mean ± standard deviation (SD) and median with inter-quartile range (IQR) were used to elucidate the demographic data. All tables for age, gender, visual acuity and clinical features were drawn by using Microsoft Excel (Microsoft Corporation 2018, Redmond, USA). Chi-squared test (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP) was used for univariate analysis to detect significant differences in the distribution of demographic features between patients with FECD and the overall population.

**Results**

**Prevalence:** Of the 3,082,727 new patients who presented across the eye care network during the study period, 2570 patients

![Figure 1](image-url)
were diagnosed with FECD in at least one eye, translating into a prevalence rate of 0.08% (95%CI:±0.0008%) or 834/million patients seen in the clinics.

Age: The mean age of the patients was 59.54 ± 12.63 years while the median age was 61 (IQR: 52–68) years. The most common age group of the patients was distributed between 61 and 70 years (n = 867; 33.74%) followed by 51 and 60 years (n = 676; 26.3%). The distribution of patients in each age-decade is presented in Fig. 3. A comparison of clinical parameters in those who were under 40 years versus over 40 years is described in Table 1.

Sex: There were 886 male (34.47%) and 1684 female (65.53%) patients. The overall distribution of FECD was significantly greater in females (0.12%; 1684/1,423,295) when compared to males (0.05%; 886/1,659,432) and was statistically significant (P ≤ 0.00001). Among the patients diagnosed with FECD, the mean and median age were 60.53 ± 13.29 and 63 (IQR: 53–69) years for men and 59.01 ± 12.2 and 60 (IQR: 51–67) years for women, respectively. The overall mode was 66 years and 69 years in men and 66 years in women.

Urban–Rural Distribution: Of the 2570 patients with FECD, 1236 (48.09%) were from an urban locality, 752 (29.26%) were from a rural locality and 582 (22.65%) patients presented from the metropolitan region. The overall prevalence of FECD in the metropolitan community (0.16%; 582/358,434) was higher when compared to the urban (0.09%; 1236/1,341,267) or rural (0.05%; 752/1,383,026) community and was statistically significant (P ≤ 0.00001).

Socio-economic status: Of the 2570 patients with FECD, there were 230 patients (8.95%) from the lower socioeconomic class, 1860 (72.37%) from the lower-middle class, 293 (11.4%) from the upper-middle class and 187 (7.28%) from the upper class. The overall prevalence of FECD was significantly higher in the higher socioeconomic strata (0.1%; 2340/2,363,156) as compared to the lower socioeconomic strata (0.03%; 230/719,571) but was statistically significant (P ≤ 0.00001).

Occupation: Of the 2570 patients with FECD, 1263 (49.14%) were homemakers; 597 (23.23%) were professionals; 403 (15.68%) were retired individuals; 86 (3.35%) were agricultural workers; 75 (2.92%) were manual laborers; 14 (0.54%) were students and in the remaining 132 patients (5.14%), the occupational category was not available or applicable. The overall prevalence of FECD in retired individuals (0.4%, 403/99,637) was significantly higher (P < 0.00001) in comparison to other professions.

Presenting Visual Acuity: In the 5140 eyes, 3074 eyes (59.81%) had mild or no visual impairment (<20/70), 781 eyes (15.19%) had moderate visual impairment (>20/70 to 20/200), 172 eyes (3.35%) had severe visual impairment (>20/200 to 20/400), 549 eyes (10.68%) had blindness (>20/400 to 20/1200), 71 eyes (1.38%) had blindness (>20/1200 to PL), 18 eyes (0.35%) had blindness (NLP), and in 475 eyes (9.24%), the visual acuity was undetermined or unspecified. The average logMAR was 0.61 ± 0.81 at presentation. Family history was documented in 33 patients (1.28%).

Corneal Findings: Among the 5140 eyes, guttae was seen in 3939 eyes (76.63%), corneal scar in 1182 (23%), stromal edema in 1117 (21.73%), endothelial folds in 607 (11.81%), epithelial bullae in 548 (10.66%), epithelial microcysts in 207 (4.03%), corneal vascularization in 207 (4.03%) and sub-epithelial fibrosis in 90 (1.75%) eyes.

Intraocular Pressure: Among the 5140 eyes, 0–9 mmHg of intraocular pressure was seen in 148 eyes (2.88%), 10–21 mmHg in 4699 eyes (91.42%), >21 mmHg in 72 eyes (1.4%) and deferred in 221 eyes (4.3%).
### Table 1: Comparison of patients with age <40 years versus >40 years with FECD

| Parameter                              | <40 years | %    | >40 years | %    | P     |
|----------------------------------------|-----------|------|-----------|------|-------|
| Total Patients                         | 209       | 8.13%| 2361      | 91.87%| NA    |
| Sex                                    |           |      |           |      |       |
| Male                                   | 77        | 36.84%| 809       | 34.27%| 0.60  |
| Female                                 | 132       | 63.16%| 1552      | 65.73%| 0.73  |
| Age (in years)                         |           |      |           |      |       |
| Average Age                            |           |      |           |      |       |
| 0-10                                   | 1         | 0.48%| NA        | NA   | NA    |
| 11-20                                  | 5         | 2.39%| NA        | NA   | NA    |
| 21-30                                  | 53        | 25.36%| NA       | NA   | NA    |
| 31-40                                  | 150       | 71.77%| NA        | NA   | NA    |
| 41-50                                  | NA        | NA   | 356       | 15.08%| NA    |
| 51-60                                  | NA        | NA   | 676       | 28.63%| NA    |
| 61-70                                  | NA        | NA   | 867       | 36.72%| NA    |
| 71-80                                  | NA        | NA   | 379       | 16.05%| NA    |
| 81-90                                  | NA        | NA   | 77        | 3.26% | NA    |
| 91-100                                 | NA        | NA   | 6         | 0.25% | NA    |
| Socioeconomic status                   |           |      |           |      |       |
| Lower                                  | 19        | 9.09%| 211       | 8.94%| 0.95  |
| Lower-Middle                           | 168       | 80.38%| 1692      | 71.66%| 0.29  |
| Upper-Middle                           | 13        | 6.22%| 280       | 11.86%| 0.03  |
| Upper                                  | 9         | 4.31%| 178       | 7.54% | 0.10  |
| Visual acuity                          |           |      |           |      |       |
| Mild or No Visual Impairment 0         | 312       | 74.64%| 2762      | 58.49%| 0.002 |
| Moderate Visual Impairment 1           | 37        | 8.85%| 744       | 15.76%| 0.001 |
| Severe Visual Impairment 2             | 4         | 0.96%| 168       | 3.56% | 0.006 |
| Blindness 3                            | 15        | 3.59%| 534       | 11.31%| <0.0001|
| Blindness 4                            | 2         | 0.48%| 69        | 1.46% | 0.10  |
| Blindness 5                            | 0         | 0.00%| 18        | 0.38% | NA    |
| Undetermined or Unspecified            | 48        | 11.48%| 427       | 9.04% | 0.14  |
| Ocular Comorbidities                  |           |      |           |      |       |
| Cataract                               | 38        | 9.09%| 2394      | 50.70%| <0.0001|
| Glaucoma                               | 6         | 1.44%| 271       | 5.74% | 0.0003|
| AMD                                    | 0         | 0.00%| 27        | 0.57% | NA    |
| BSK                                    | 0         | 0.00%| 2         | 0.04% | NA    |
| Vascular Occlusions                    | 0         | 0.00%| 14        | 0.30% | NA    |
| Clinical Features                      |           |      |           |      |       |
| Guttae                                 | 353       | 84.45%| 3586      | 75.94%| 0.16  |
| Stromal Scar                           | 84        | 20.10%| 1098      | 23.25%| 0.24  |
| Stromal Edema                          | 64        | 15.31%| 1053      | 22.30%| 0.006 |
| Descemet Membrane Folds                | 24        | 5.74%| 583       | 12.35%| 0.0003|
| Epithelial Bullae                      | 41        | 9.81%| 507       | 10.74%| 0.60  |
| Epithelial Microcysts                  | 10        | 2.39%| 197       | 4.17% | 0.09  |
| Vascularization                        | 8         | 1.91%| 199       | 4.21% | 0.03  |
| Sub-Epithelial Fibrosis                | 16        | 3.83%| 74        | 1.57% | 0.001 |
| Intracocular Pressure                  |           |      |           |      |       |
| 0-9 mmHg                               | 4         | 0.96%| 144       | 3.05% | 0.02  |
| 10-21 mmHg                             | 353       | 84.45%| 4346      | 92.04%| 0.25  |
| >21 mmHg                               | 1         | 0.24%| 71        | 1.50% | 0.04  |
| Defer                                  | 60        | 14.35%| 161       | 3.41% | <0.0001|

Contd...
Ocular Comorbidities: Among the 5140 eyes, an associated ocular comorbidity of cataract was seen in 2432 eyes (47.32%), glaucoma in 277 (5.39%), age-related macular degeneration in 27 (0.53%), vascular occlusions in 14 (0.27%) eyes and band-shaped keratopathy in 2 (0.04%) eyes.

Surgical Treatment: Among the 5140 patients, surgical intervention of endothelial keratoplasty (EK) was performed in 811 eyes (15.78%), and a combined procedure of cataract surgery and keratoplasty was performed in 488 eyes (9.49%). Of the total EKs, Descemet’s stripping endothelial keratoplasty (DSEK) was performed in 541 eyes (10.53%) and Descemet membrane endothelial keratoplasty (DMEK) was performed in 270 eyes (5.25%). There were 1026 eyes (19.96%) that underwent cataract surgery, of which 49 (10%) required an endothelial keratoplasty at an average interval of 361 ± 288 days. The detailed table describing the surgical interventions and the visual acuity is detailed in Table 2. The average follow-up of the patients was 361 ± 579 days with an average of 4 ± 6 visits.

Discussion

This study sought to describe the clinical profile and demographic distribution of Fuchs’ endothelial corneal dystrophy (FECD) in a large cohort of patients presenting to a multi-tiered hospital network in India using electronic medical records–driven big data analytics. The primary purpose of the study was to determine the relative proportion and demographic profile of the FECD in the clinical care setup. The overall prevalence of FECD was 0.08% in patients who presented between 2018 and 2021 (four-year period).

The clinical diagnosis of FECD is based on guttae seen on slit-lamp biomicroscopy. The nature and extent of guttae that occur in FECD is varied and the impact of guttae on vision and their correlation with visual acuity is complex. Additionally, the severity of FECD disease and the progression of the condition to a stage of clinical corneal edema can vary. Many patients with FECD may not have visual complaints and are either diagnosed with the condition incidentally in the clinics or when the visual acuity is affected at a later age coinciding with cataract development. In a study by Barrera-Sanchez M et al., on 102 eyes of 51 Mexican-mestizo population, a majority of eyes (57.8%) with FECD were asymptomatic and keratoplasty was required in 17.6% of eyes. In our study, we found that the disease caused mild or no visual impairment in half (59.81%) of the affected eyes and only over a tenth (16.81%) of the eyes required a keratoplasty.

The disease is known to be commoner in females. Except for a few, most studies have reported a male/female ratio of 2.5:1 to 3.5:1. A similar observation was noted in this study where female preponderance was seen in 65.53%. In comparison to nationwide epidemiological study in Taiwanese population, which identified low socioeconomic status as a risk factor for FECD, our study found a significantly higher prevalence in higher socioeconomic status. We did not see any association with ocular allergic conditions that was found in the same study.

FECD is known to occur in two forms: early-onset and late-onset variants. The distinction of the two forms is not always possible as genetic testing is not a routine practice. Also, the exact age of onset of the disease and evolution of the condition in the longitudinal follow-up is not possible. Hence, we compared the clinical and demographic parameters in younger versus older patients taking 40 years as an age divide [Table 1]. The females were more commonly affected in both <40 and >40 years (63.16% versus 65.73%, respectively), although the difference was not statistically significant. Visual acuity impairment was notably more significant in those older than 40 years, due to associated cataract in the above 40 years age group. Corneal edema, Descemet membrane folds, vascularization and subepithelial fibrosis were significantly more in those above 40 years. The need for EK was significantly higher in the > 40 years age group.

Cataract surgery alone is considered in FECD when patient has no clinical symptoms suggestive of endothelial compromise and cornea is compact without evident anterior stromal changes and Descemet membrane thickening. However, the risk of FECD disease progression exists post cataract surgery. We found that of the 1026 eyes that underwent cataract surgery, 49 (10%) needed EK later.

This is the largest series of FECD patients in an Indian population. The study lends insight into the sociodemographics, clinical presentation, visual impairment, and treatment aspects of FECD in a large cohort of patients. FECD can vary from mild, asymptomatic to a severe form with corneal edema. Furthermore, the condition has ethnic differences in the mode of presentation. Our study found that 16.81% of FECD required keratoplasty. Of those patients with FECD that had cataract surgery alone, ~10% eventually needed keratoplasty after a few years. This information is important and can be used in clinical practice for prognostication and decision-making on cataract surgery alone in those with guttae but no clinically apparent
Table 2: Surgical distribution of patients with Fuchs endothelial dystrophy and visual acuity

| Surgical Intervention          | Eyes | %    | Pre-Op* | Post-Op* |
|--------------------------------|------|------|---------|----------|
| Cataract                       | 1026 | 19.96% | 0.88±0.84 | 0.44±0.62 |
| Endothelial Keratoplasty       | 811  | 15.78% | 1.01±0.85 | 0.68±0.74 |
| DSEK                           | 541  | 10.53% | 1.11±0.89 | 0.79±0.78 |
| DMEK                           | 270  | 5.25%  | 0.78±0.71 | 0.46±0.58 |
| Penetrating Keratoplasty       | 53   | 1.03%  | 1.98±1.08 | 1.18±0.85 |
| Cataract + Keratoplasty        | 488  | 9.49%  | 0.98±0.87 | 0.60±0.70 |
| Glaucoma                       | 21   | 0.41%  | 0.47±0.33 | 0.73±0.82 |
| Others                         | 68   | 1.32%  | 0.96±1.07 | 0.82±0.95 |
| ASP                            | 6    | 0.12%  | 2.45±1.29 | 2.50±0.87 |

*Visual acuity in LogMAR

The prevalence of primary cornea guttata and morphology of 15.78% was found to be common in Japanese patients with cataract: Specular microscopic observations. Jpn J Ophthalmol 1996;40:520-5.

Affshari NA, Pittard AB, Siddiqui A, Klintworth GK. Clinical study of Fuchs corneal endothelial dystrophy leading to penetrating keratoplasty: A 30-year experience. Arch Ophthalmol 2006;124:777-80.

Conflicts of interest

Nil.

Financial support and sponsorship

The authors wish to acknowledge the support of our department of eyeSmart EMR & AEye team specially Mr Ranganath Vadapalli and Mr Mohammad Pasha.

References

1. Wilson SE, Bourne WM. Fuchs’ dystrophy. Cornea 1988;7:2-18.
2. Fuchs E. Dystrophia epithelialis corneae. Albr von Graefe’s Arch für Ophthalmol 1910;76:478–508.
3. Gear EL. Dystrophy of the corneal endothelium (Cornea Guttata), with report of a histologic examination. Trans Am Ophthalmol Soc 1933;31:48-59.
4. Lorenzetti DW, Uotila MH, Parikh N, Kaufman HE. Central cornea guttata. Incidence in the general population. Am J Ophthalmol 1967;64:1155-8.
5. Zoega GM, Fujisawa A, Sasaki H, Kubota A, Sasaki K, Kitagawa K, et al. Prevalence and risk factors for cornea guttata in the Reykjavik Eye Study. Ophthalmology 2006;113:565-9.
6. Nagaki Y, Hayasaka S, Kitagawa K, Yamamoto S. Primary cornea guttata in Japanese patients with cataract: Specular microscopic observations. Jpn J Ophthalmol 1996;40:520-5.
7. Goar EL. Dystrophy of the corneal endothelium (Cornea Guttata), with report of a histologic examination. Trans Am Ophthalmol Soc 1933;31:48-59.
8. Lorenzetti DW, Uotila MH, Parikh N, Kaufman HE. Central cornea guttata. Incidence in the general population. Am J Ophthalmol 1967;64:1155-8.
9. Zoega GM, Fujisawa A, Sasaki H, Kubota A, Sasaki K, Kitagawa K, et al. Prevalence and risk factors for cornea guttata in the Reykjavik Eye Study. Ophthalmology 2006;113:565-9.
10. Nagaki Y, Hayasaka S, Kitagawa K, Yamamoto S. Primary cornea guttata in Japanese patients with cataract: Specular microscopic observations. Jpn J Ophthalmol 1996;40:520-5.
11. Afshari NA, Pittard AB, Siddiqui A, Klintworth GK. Clinical study of Fuchs corneal endothelial dystrophy leading to penetrating keratoplasty: A 30-year experience. Arch Ophthalmol 2006;124:777-80.
12. Magovern M, Beauchamp GR, McTigue JW, Fine BS, Baumiller RC. Inheritance of Fuchs’ combined dystrophy. Ophthalmol 1979;86:1897-923.
13. Das AV, Basu S. Indications and prognosis for keratoplasty in eyes with severe visual impairment and blindness due to corneal disease in India. Br J Ophthalmol 2021;105:17-21.
14. Das AV, Chaurasia S. Clinical profile and demographic distribution of corneal dystrophies in India: A study of 4198 patients. Cornea 2021;40:548-53.
15. Das AV, Mohamed A, Chaurasia S. Recent indications of endothelial keratoplasty at a tertiary eye care center in South India. Int Ophthalmol 2021;41:3277-85.
16. Rao GN, Khanna RC, Athota SM, Rajeshker V, Rani PK. Integrated model of primary and secondary eye care for underserved rural areas: The L V Prasad Eye Institute experience. Indian J Ophthalmol 2012;60:396-400.
17. Das AV, Kammari P, Vadapalli R, Basu S. Big data and the eyeSmart electronic medical record system-An 8-year experience from a three-tier eye care network in India. Indian J Ophthalmol 2020;68:327-32.
18. World Health Organization. (2008). Change the definition of blindness. Available from: https://www.who.int/blindness/Change%20the%20Definition%20of%20Blindness.pdf.
19. Wacker K, Reinhard T, Maier P. Pathogenese, diagnost und klinik der Fuchs-endotheldystrophie [Pathogenesis and diagnostic evaluation of Fuchs’ endothelial corneal dystrophy]. Ophthalmologe 2019;116:221-7.
20. Barrera-Sanchez M, Hernandez-Camarena JC, Ruiz-Lozoano RE, Valdez-Garcia JE, Rodriguez-Garcia A. Demographic profile and clinical course of Fuchs endothelial corneal dystrophy in Mexican patients. Int Ophthalmol 2022;42:1299-309.
21. Chang YS, Ho CH, Wang Jj, Tseng SH, Jan RL. The Sociodemographic and risk factors for Fuchs’ endothelial dystrophy: A nationwide, matched case-control study in Taiwan. J Pers Med 2022;12:305.
22. Kitagawa K, Kojima M, Sasaki H, Shui YB, Chew SJ, Cheng HM, et al. Prevalence of primary cornea guttata and morphology of corneal endothelium in aging Japanese and Singaporean subjects. Ophthalmic Res 2002;34:135–8.
23. Zhang J, McGhee CNJ, Patel DV. The molecular basis of Fuchs’ endothelial corneal dystrophy. Mol Diagn Ther 2019;23:97-112.
24. Chaurasia S, Ramappa M. Fuchs endothelial corneal dystrophy in a child. Cornea 2017;36:e17-8.
25. Moshifir M, Huynh R, Ellis JH. Cataract surgery and intraocular lens placement in patients with Fuchs corneal dystrophy: A review of the current literature. Curr Opin Ophthalmol 2022;33:21-7.